MENU
BEAM
AS OF
Feb 3 closing price
Price
$27.89
Change
+$0.02 (+0.07%)
Capitalization
2.83B
27 days until earnings call
Intraday BUY SELL Signals
+Compare
BEAM
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$27.89
Change
+$0.02 (+0.07%)
Capitalization
2.83B

BEAM Beam Therapeutics Forecast, Technical & Fundamental Analysis

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases... Show more

BEAM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for BEAM with price predictions
Feb 02, 2026

BEAM sees MACD Histogram just turned negative

BEAM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BEAM moved out of overbought territory on January 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on January 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAM as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BEAM broke above its upper Bollinger Band on January 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

BEAM moved above its 50-day moving average on February 02, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 169 cases where BEAM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.930) is normal, around the industry mean (27.778). P/E Ratio (0.000) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (46.948) is also within normal values, averaging (333.006).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BEAM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

BEAM is expected to report earnings to fall 8.18% to -100 cents per share on March 03

Beam Therapeutics BEAM Stock Earnings Reports
Q4'25
Est.
$-1.01
Q3'25
Missed
by $0.05
Q2'25
Beat
by $0.11
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.18
The last earnings report on November 04 showed earnings per share of -110 cents, missing the estimate of -104 cents. With 1.21M shares outstanding, the current market capitalization sits at 2.83B.
A.I. Advisor
published General Information

General Information

a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
238 Main Street
Phone
+1 857 327-8775
Employees
436
Web
https://www.beamtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MATFX18.380.15
+0.82%
Matthews Asia Innovators Investor
MCRFX14.030.02
+0.14%
BlackRock Mid-Cap Value Investor C
ARFFX18.78N/A
N/A
Ariel Focus Investor
PASRX21.29-0.09
-0.42%
Putnam Dynamic Asset Allocation Gr R
MGRQX43.12-0.28
-0.65%
MFS International Growth R2

BEAM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.09%
CRSP - BEAM
72%
Closely correlated
+2.70%
RXRX - BEAM
62%
Loosely correlated
-0.24%
NTLA - BEAM
62%
Loosely correlated
-0.68%
PRME - BEAM
61%
Loosely correlated
-0.26%
VIR - BEAM
58%
Loosely correlated
+3.63%
More

Groups containing BEAM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.09%
BEAM
(2 stocks)
88%
Closely correlated
+0.62%